320 related articles for article (PubMed ID: 24119020)
1. Novel simplified yeast-based assays of regulators of p53-MDMX interaction and p53 transcriptional activity.
Leão M; Gomes S; Soares J; Bessa C; Maciel C; Ciribilli Y; Pereira C; Inga A; Saraiva L
FEBS J; 2013 Dec; 280(24):6498-507. PubMed ID: 24119020
[TBL] [Abstract][Full Text] [Related]
2. Studying p53 family proteins in yeast: induction of autophagic cell death and modulation by interactors and small molecules.
Leão M; Gomes S; Bessa C; Soares J; Raimundo L; Monti P; Fronza G; Pereira C; Saraiva L
Exp Cell Res; 2015 Jan; 330(1):164-77. PubMed ID: 25265062
[TBL] [Abstract][Full Text] [Related]
3. A tryptophanol-derived oxazolopiperidone lactam is cytotoxic against tumors via inhibition of p53 interaction with murine double minute proteins.
Soares J; Raimundo L; Pereira NA; dos Santos DJ; Pérez M; Queiroz G; Leão M; Santos MM; Saraiva L
Pharmacol Res; 2015; 95-96():42-52. PubMed ID: 25814188
[TBL] [Abstract][Full Text] [Related]
4. Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors.
Noguchi T; Oishi S; Honda K; Kondoh Y; Saito T; Kubo T; Kaneda M; Ohno H; Osada H; Fujii N
Bioorg Med Chem Lett; 2013 Jul; 23(13):3802-5. PubMed ID: 23726030
[TBL] [Abstract][Full Text] [Related]
5. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
Hu B; Gilkes DM; Chen J
Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
[TBL] [Abstract][Full Text] [Related]
6. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
[TBL] [Abstract][Full Text] [Related]
7. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
[TBL] [Abstract][Full Text] [Related]
8. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
[TBL] [Abstract][Full Text] [Related]
9. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.
Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM
Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697
[TBL] [Abstract][Full Text] [Related]
10. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
[TBL] [Abstract][Full Text] [Related]
11. Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells.
Mrkvová Z; Uldrijan S; Pombinho A; Bartůněk P; Slaninová I
Molecules; 2019 Jun; 24(11):. PubMed ID: 31181622
[TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of the first small molecule inhibitor of MDMX.
Reed D; Shen Y; Shelat AA; Arnold LA; Ferreira AM; Zhu F; Mills N; Smithson DC; Regni CA; Bashford D; Cicero SA; Schulman BA; Jochemsen AG; Guy RK; Dyer MA
J Biol Chem; 2010 Apr; 285(14):10786-96. PubMed ID: 20080970
[TBL] [Abstract][Full Text] [Related]
13. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
Tisato V; Voltan R; Gonelli A; Secchiero P; Zauli G
J Hematol Oncol; 2017 Jul; 10(1):133. PubMed ID: 28673313
[TBL] [Abstract][Full Text] [Related]
14. An Update on MDMX and Dual MDM2/X Inhibitors.
Espadinha M; Barcherini V; Lopes EA; Santos MMM
Curr Top Med Chem; 2018; 18(8):647-660. PubMed ID: 29866007
[TBL] [Abstract][Full Text] [Related]
15. A Fusion Protein of the p53 Transaction Domain and the p53-Binding Domain of the Oncoprotein MdmX as an Efficient System for High-Throughput Screening of MdmX Inhibitors.
Chen R; Zhou J; Qin L; Chen Y; Huang Y; Liu H; Su Z
Biochemistry; 2017 Jun; 56(25):3273-3282. PubMed ID: 28581721
[TBL] [Abstract][Full Text] [Related]
16. p53 binds the mdmx mRNA and controls its translation.
Tournillon AS; López I; Malbert-Colas L; Findakly S; Naski N; Olivares-Illana V; Karakostis K; Vojtesek B; Nylander K; Fåhraeus R
Oncogene; 2017 Feb; 36(5):723-730. PubMed ID: 27375027
[TBL] [Abstract][Full Text] [Related]
17. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).
Drakos E; Singh RR; Rassidakis GZ; Schlette E; Li J; Claret FX; Ford RJ; Vega F; Medeiros LJ
Leukemia; 2011 May; 25(5):856-67. PubMed ID: 21394100
[TBL] [Abstract][Full Text] [Related]
18. p53 transactivation and the impact of mutations, cofactors and small molecules using a simplified yeast-based screening system.
Andreotti V; Ciribilli Y; Monti P; Bisio A; Lion M; Jordan J; Fronza G; Menichini P; Resnick MA; Inga A
PLoS One; 2011; 6(6):e20643. PubMed ID: 21674059
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a new small-molecule inhibitor of p53-MDM2 interaction using a yeast-based approach.
Leão M; Pereira C; Bisio A; Ciribilli Y; Paiva AM; Machado N; Palmeira A; Fernandes MX; Sousa E; Pinto M; Inga A; Saraiva L
Biochem Pharmacol; 2013 May; 85(9):1234-45. PubMed ID: 23428467
[TBL] [Abstract][Full Text] [Related]
20. Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase.
Okamoto K; Taya Y; Nakagama H
FEBS Lett; 2009 Sep; 583(17):2710-4. PubMed ID: 19619542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]